Drug Trial Radar · NCT02631044
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
387
Actual
Start
Jan 6, 2016
Primary completion
May 16, 2024
Study completion May 16, 2024
Sponsor
- Lead sponsor
- Juno Therapeutics, a Subsidiary of CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.
Conditions
- Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle-cell Lymphoma
- Primary Mediastinal B-cell Lymphoma
Interventions
JCAR017 (lisocabtagene maraleucel) single-dose scheduleBiological
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
JCAR017 (lisocabtagene maraleucel) 2-dose scheduleBiological
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-related adverse events (AEs) as assessed by CTCAE v4.03Time frame: Up to 730 days after the final JCAR017 infusion
- Dose-limiting toxicities of JCAR017Time frame: 28 days after first (single-dose schedule) or second (2-dose schedule) JCAR017 infusion
- Objective response rate (ORR)Time frame: 24 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0006
Birmingham, Alabama
Local Institution - 0007
Duarte, California
Local Institution - 0010
San Francisco, California
Local Institution - 0020
Aurora, Colorado
Local Institution - 0019
Atlanta, Georgia
Local Institution - 0003
Chicago, Illinois
Local Institution - 0005
Boston, Massachusetts
Local Institution - 0015
Boston, Massachusetts
Local Institution - 0008
Omaha, Nebraska
Local Institution - 0001
New York, New York
Local Institution - 0021
Charlotte, North Carolina
Local Institution - 0029
Pittsburgh, Pennsylvania
Local Institution - 0002
Houston, Texas
Local Institution - 0018
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.